Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06773897 · ClinicalTrials.gov registry record
Rutgers University Study of the Genetics of Breast Cancer.
A clinical trial of Breast Cancer and Breast Cancer Risk, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- 25,000
- Enrollment target
- 1
- Study location
NCT06773897: Recruiting study of Breast Cancer and Breast Cancer Risk, sponsored by Rutgers, The State University of New Jersey.
NCT06773897 is a study of Breast Cancer and Breast Cancer Risk that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 25,000 participants, above the 2,783-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (798% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06773897, a study of Breast Cancer and Breast Cancer Risk, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- 25,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn more about how genes impact the risk of breast cancer. Anyone 18 or older living in the US is eligible, and a diagnosis of cancer is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.
Primary Outcome
Genetic factors will be measured through whole exome sequencing along with genotyping of common variants, and then correlated with breast cancer and breast cancer subtype.
Conditions Studied
Interventions
- GENETIC Saliva sample
- OTHER Health Surveys
Study Locations (1)
New Jersey
- Rutgers University - Piscataway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,000 participants |
| Start Date | 2024-04-15 |
| Est. Completion | 2027-04-30 |
What NCT06773897 shows while recruiting
NCT06773897 is an observational study that tracks outcomes without assigning an intervention. Its 25,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,783-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (798% higher).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Saliva sample is the first listed.
NCT06773897 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06773897 about?
NCT06773897 is a clinical study titled "Rutgers University Study of the Genetics of Breast Cancer.". The goal of this observational study is to learn more about how genes impact the risk of breast cancer. Anyone 18 or older living in the US is eligible, and a diagnosis of cancer is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a sa...
What is the current status of trial NCT06773897?
This trial is currently recruiting. The enrollment target is 25,000 participants. The study started on 2024-04-15. Estimated completion is 2027-04-30.
What conditions does trial NCT06773897 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Cancer Risk, Breast Cancer Prevention.
What interventions are being tested in trial NCT06773897?
The interventions under investigation include: Saliva sample (GENETIC), Health Surveys (OTHER).
Who is sponsoring clinical trial NCT06773897?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06773897 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06773897's enrollment target sits among peer trials
25,000 7th of 1224 higher than 1,217 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
- NCT06589310 · 25,000 participants
Falcon Real World Evidence Registry
- NCT06774417 · 25,000 participants · NA
Digital Strategies to Advance Help-Seeking - Aim 3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI